
Minimally Invasive Interventional Device Developer

The 26th Annual Conference of the Chinese Society of Cardiology and the 22nd Congress of Interventional Cardiology(CSC2024 and CIT2024) were recently held in Changsha. This grand event, in collaboration with the 4C and X²-ICC conferences, greatly enhanced the professionalism and influence of the meeting through the efficient integration of various academic resources.During the conference, 216 academic exchange activities were meticulously planned, covering 1,118 in-depth academic reports, and attracting the active participation of 13,436 cardiovascular professionals from around the world.
In the field of medical technology innovation in China, Valgen Medtech has demonstrated profound technical expertise and innovative achievements, particularly in interventional treatments for structural heart diseases.This ConferenceValgen Medtech successfully presented three live surgical demonstration broadcasts, fully showcasing the excellent performance and practical application effects of its "flagship" product, the DragonFly™ Transcatheter Mitral Valve Clip System., which further highlights Valgen Medtech's strength, determination, and significant achievements in promoting technological innovation and progress in China's medical field.
TEER in Patients with Severe Mitral Regurgitation and Type II Barlow's Disease
Surgical demonstration was conducted by the team of Academician Jian'an Wang from the Second Affiliated Hospital of Zhejiang University School of Medicine, successfully completing a TEER surgery with extremely high risk and complex anatomical structure. The patient was a 75-year-old male admitted for recurrent chest tightness and shortness of breath over two years, with recurrence one month prior. A grade 4-5/6 systolic blowing murmur was heard in the apical area. His medical history included a previous craniotomy and drainage procedure, more than 10 years of hypertension, and Parkinson's disease. Echocardiography revealed extensive prolapse of the anterior and posterior mitral valve leaflets, particularly prominent in region 2, accompanied by eccentric severe regurgitation. Barlow syndrome was strongly suspected, along with mild tricuspid regurgitation. Both the anterior and posterior leaflets of regions 1 and 2 of the mitral valve were prolapsed and redundant, involving C1, making it extremely challenging to manage. After comprehensive evaluation, the team utilized the domestically innovative mitral valve repair device DragonFly™ (developed by Valgen Medtech Co., Ltd.) to first place a long-width (XW0612) mitral clip in the 2-to-3 region to address medial prolapse and regurgitation. Subsequently, a second long-width (XW0612) mitral clip was placed side-by-side on the L side of the first clip.
After the mitral valve clip was released, ultrasound showed a significant improvement in the patient's regurgitation. Although prolapse was still present at the junction of zone 1 to the periphery, the regurgitant volume was minimal, and after discussion, it was decided not to implant a third mitral valve clip. Notably, the quantified knob design of DragonFly™ quantifies the angle of catheter bending, greatly enhancing intraoperative efficiency; the case took only one hour from atrial septal puncture to completion.
TEER in Patients with Severe Mitral Regurgitation of Type I Atrial Mitral Valve
The team of Academician Jian'an Wang from the Second Affiliated Hospital of Zhejiang University School of Medicine once again demonstrated a TEER surgery for severe mitral regurgitation. The patient was a 76-year-old woman. Echocardiography showed severe mitral regurgitation, mild aortic regurgitation, and moderate tricuspid regurgitation. P2P3 tethering was observed, with regurgitation visible in zones 1-3, no effective coaptation, and a maximum leaflet gap of approximately 7mm, indicating an extremely challenging surgery. After comprehensive evaluation, the team first placed a short-wide (SW0609) model mitral clip in zone 2-3 and zone 2 using DragonFly™, followed by placing a short-narrow (SN0409) model mitral clip in zone 2-1.

During the operation, the team implanted a short and wide (SW0609) mitral valve clip slightly towards zone 3 in zone 2. After clipping, the regurgitation improved slightly, but there was still a large amount of 3-4+ regurgitation on the inner and outer sides. Considering that the regurgitation in zone 3 could not be completely resolved, it was decided not to address the regurgitation in zone 3, and the clip was released. A second short and wide (SW0609) clip was implanted side by side on the L side of the first mitral valve clip. After clipping, the residual regurgitation was 2+, and the transvalvular pressure gradient was 2mmHg. Due to the patient's annular dilation and lack of leaflet coaptation, the risk of leaflet tearing during the procedure was very high. After considering whether to implant a third mitral valve clip, it was ultimately decided to proceed with the implantation. A short and narrow (SN0409) mitral valve clip was implanted in zone 2 slightly towards zone 1. After clipping, the residual regurgitation was 1+, and the transvalvular pressure gradient was 3mmHg, concluding the surgery perfectly. The independent capture function of DragonFly™ greatly enhanced the efficiency of leaflet capture. Its unique stabilizer frame design allowed for very stable and safe release of leaflet tension during the closure of the mitral valve clip, avoiding the risk of tearing, which was significantly effective in this operation.
TEER for Type II Posterior Mitral Leaflet Prolapse with Severe Regurgitation
Prof. An Guipeng's Team from Qilu Hospital of Shandong University Successfully Demonstrates TEER Procedure on a 32kg Patient with Atrial Septal Aneurysm, Patent Foramen Ovale, and Severe Osteoporosis
Due to the formation of an aneurysm in the patient's atrial septum and the presence of a patent foramen ovale, the puncture was extremely challenging. During the procedure, the team performed the puncture as high and posterior as possible at the fossa ovalis of the atrial septum, with a final puncture height of 4.2 cm. Initially, a mitral valve clip of length-width model (XW0612) was implanted slightly towards zone 1 within zone 2. After clipping, residual regurgitation remained on the L side. Following discussion, it was decided to implant a second shorter and narrower mitral valve clip (model SN0409) side by side on the L side of the first clip in zone 1. After clipping, functional regurgitation of 1+ was present between the two mitral valve clips, with a transvalvular pressure gradient of 2 mmHg; the patient recovered well. The graduated knob and three-segment adjustable catheter body design of DragonFly™ provide clear scale indications for both the guiding sheath and the middle sheath during intraoperative bending adjustments, and both can be independently adjusted in the A/P direction, playing a very important role in the procedure.
Valgen Medtech deeply understands that on the journey to pursue high-quality development of innovative medical technology in China, we must remain true to our original aspiration to achieve ultimate success. Facing challenges and difficulties, we will not retreat but strengthen our core values, moving forward with the courage to innovate, professional excellence, and deep care for patients, continuously exploring and practicing Valgen's unique medical approach. We also recognize that value is not only reflected in technological breakthroughs and service optimization but, more importantly, in contributions to society and the responsibility we shoulder. With passion and perseverance, we will take firm steps toward a bright future of high-quality development for innovative medical technology in China, steadfastly advancing.
Valgen Medtech Co., Ltd. was established in 2015 and focuses on interventional treatment products and technologies for mitral and tricuspid valve diseases. The company has applied for over 600 patents globally, with more than 200 already authorized. Four innovative products independently developed by the company have passed the special review process for innovative medical devices by the pharmaceutical regulatory authority. Its range of interventional treatment devices, represented by the Dragon series, will greatly enrich clinical options in China for treating structural heart diseases.
Core Product DragonFly™ Transcatheter Mitral Valve Clip System – As the first transvenous edge-to-edge repair product independently developed in China, it has been approved by the NMPA for official launch in China. The product is supported by the national "14th Five-Year Plan" key research and development program. In addition, other currently marketed products include Sister Pu™ Medical Radiation Protection Screen, Magpie™ Balloon Dilation Catheter, DragonPath™ Atrial Septal Puncture System, and a series of guidewires.